Reference Citation Analysis: Find an Article, Find a Category, Find a Journal, Find a Scholar

Total Articles

169
(from Reference Citation Analysis)

Article PDFs (2)

Cited by ≥ 1 (31)

Searched Name

R. Govindan

Ranked By

Results Analysis

Year Published Analysis
Article Type Analysis
Publication Title Analysis
Category Analysis

Results Analysis

Number	Citation Analysis
26	Bueno R, Harpole D, Tsao M, Beer D, Watson M, Shepherd F, Richards W, Ballman K, Wang X, Chen Z, Govindan R, Chen G, Rivard C, Hirsch F. OA13.01 SPECS2 Lung Cancer Consortium Prospective Multicenter Validation of Prognostic Signature for Early Stage Squamous Lung Cancer. J Thorac Oncol 2019. [DOI: 10.1016/j.jtho.2019.08.477] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022] Abstract Collapse Key Words Collapse MESH Headings Collapse Grants Collapse
27	Owonikoko T, Kim H, Govindan R, Ready N, Reck M, Peters S, Dakhil S, Navarro A, Rodriguez-Cid J, Schenker M, Lee J, Gutierrez V, Percent I, Morgensztern D, Fairchild J, Baudelet C, Park K. Nivolumab (nivo) plus ipilimumab (ipi), nivo, or placebo (pbo) as maintenance therapy in patients (pts) with extensive disease small cell lung cancer (ED-SCLC) after first-line (1L) platinum-based chemotherapy (chemo): Results from the double-blind, randomized phase III CheckMate 451 study. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz094] [Citation(s) in RCA: 64] [Impact Index Per Article: 12.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/28/2022] Open Abstract Collapse Key Words Collapse MESH Headings Collapse Grants Collapse
28	Lam V, Hong D, Heymach J, Blumenschein G, Butler M, Johnson M, Creelan B, Gainor J, Govindan R, Mudad R, Neal J, Brophy F, Fang F, Hyland N, Holdich T, Ma Y, Trivedi T, Norry E, Amado R. Safety and anti-tumor effects of MAGE-A10c796 TCR T-cells in two clinical trials. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy424.048] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open Abstract Collapse Key Words Collapse MESH Headings Collapse Grants Collapse
29	Elamin Y, Antonoff M, Blakely C, Baggstorm M, Bivona T, Le X, Louie A, Doebele R, Rusthoven C, Lee P, Govindan R, Swisher S, Papadimitrakopoulou V, Heymach J, Gomez D. Randomized phase II trial of osimertinib with or without local consolidation therapy (LCT) for patients with EGFR-mutant metastatic NSCLC (NORTHSTAR). Ann Oncol 2018. [DOI: 10.1093/annonc/mdy292.130] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open Abstract Collapse Key Words Collapse MESH Headings Collapse Grants Collapse
30	Yu H, Chen Z, Ballman K, Watson M, Govindan R, Beer D, Bueno R, Herman M, Franklin W, Gandara D, Joshi M, Merrick D, Richards W, Rivard C, Shepherd F, Tsao M, Bokhoven A, Harpole D, Hirsch F. P1.04-23 Expression of Emerging Immunotherapy Targets in Early-Stage Squamous Lung Carcinoma. J Thorac Oncol 2018. [DOI: 10.1016/j.jtho.2018.08.738] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Abstract Collapse Key Words Collapse MESH Headings Collapse Grants Collapse
31	Ott P, Govindan R, Naing A, Friedlander T, Margolin K, Lin J, Bhardwaj N, Hellman M, Srinivasan L, Greshock J, Moles M, Gaynor R, Goldstein M, Hu-Lieskovan S. A personal neoantigen vaccine, NEO-PV-01, with anti-PD1 induces broad de novo anti-tumor immunity in patients with metastatic melanoma, NSCLC, and bladder cancer. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy288] [Citation(s) in RCA: 16] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open Abstract Collapse Key Words Collapse MESH Headings Collapse Grants Collapse
32	Oxnard G, Mandrekar S, Hillman S, Tan A, Govindan R, Wigle D, Malik S, Watt C, Gerber D, Chaft J, Dahlberg S, Kelly K, Faggen M, Stella P, Tazi K, Gandara D, Ramalingam S, Stinchcombe T. P1.16-47 Adjuvant Targeted Therapy Following Standard Adjuvant Therapy for Resected NSCLC: An Initial Report from ALCHEMIST (Alliance A151216). J Thorac Oncol 2018. [DOI: 10.1016/j.jtho.2018.08.1016] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022] Abstract Collapse Key Words Collapse MESH Headings Collapse Grants Collapse
33	Morgensztern D, Govindan R, Cobo M, Ponce Aix S, Postmus P, Lewanski C, Bennouna J, Fischer J, Juan-Vidal O, Stewart D, Ardizzoni A, Bhore R, Wolfsteiner M, Reck M, Talbot D, Ong T. P1.01-70 Efficacy and Safety of Second- or Third-Line Nab-Paclitaxel + Durvalumab in Patients with Advanced NSCLC (ABOUND.2L+). J Thorac Oncol 2018. [DOI: 10.1016/j.jtho.2018.08.626] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022] Abstract Collapse Key Words Collapse MESH Headings Collapse Grants Collapse
34	Talbot D, Govindan R, Cobo M, Ponce Aix S, Postmus P, Lewanski C, Bennouna J, Fischer J, Juan-Vidal O, Stewart D, Ardizzoni A, Bhore R, Wolfsteiner M, Reck M, Morgensztern D, Ong T. P1.01-93 Quality of Life in Patients with Advanced NSCLC Treated in Second- or Third-Line with Nab-Paclitaxel + Durvalumab: ABOUND.2L+. J Thorac Oncol 2018. [DOI: 10.1016/j.jtho.2018.08.649] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022] Abstract Collapse Key Words Collapse MESH Headings Collapse Grants Collapse
35	Govindan R. MS 02.01 Lung Cancer Genomics. J Thorac Oncol 2017. [DOI: 10.1016/j.jtho.2017.09.200] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022] Abstract Collapse Key Words Collapse MESH Headings Collapse Grants Collapse
36	Morgensztern D, Dols MC, Aix SP, Postmus P, Bennouna J, Fischer J, Vidal O, Stewart D, Fasola G, Weaver J, Wolfsteiner M, Ong T, Govindan R. MA 03.01 Nab-Paclitaxel ± CC-486 as Second-Line Treatment of Advanced NSCLC: Results from the ABOUND.2L+ Study. J Thorac Oncol 2017. [DOI: 10.1016/j.jtho.2017.09.460] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022] Abstract Collapse Key Words Collapse MESH Headings Collapse Grants Collapse
37	Govindan R, Borghaei H, He S, Kim J, Papadimitrakopoulou V. P2.01-040 Pemetrexed plus Platinum Chemotherapy with or Without Immunotherapy in Non-Squamous NSCLC: Descriptive Safety Analysis. J Thorac Oncol 2017. [DOI: 10.1016/j.jtho.2017.09.1142] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022] Abstract Collapse Key Words Collapse MESH Headings Collapse Grants Collapse
38	Morgensztern D, Ong T, Dols MC, Aix SP, Postmus P, Lewanski C, Bennouna J, Fischer J, Vidal O, Stewart D, Fasola G, Ardizoni A, Weaver J, Wolfsteiner M, Talbot D, Govindan R. ABOUND.2L+: nab-paclitaxel (nab-P) +/- CC-486 or durvalumab in previously treated patients with advanced non-small cell lung cancer (NSCLC). Ann Oncol 2017. [DOI: 10.1093/annonc/mdx440.051] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open Abstract Collapse Key Words Collapse MESH Headings Collapse Grants Collapse
39	Devarakonda S, Govindan R. TRAC(ERx)-ing lung cancer evolution. Ann Oncol 2017. [PMID: 28633461 DOI: 10.1093/annonc/mdx313] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/12/2022] Open Abstract Collapse Key Words Collapse MESH Headings Collapse Grants Collapse
40	Moreno V, Bauer T, Infante J, Govindan R, Besse B, Bertino E, Marti AM, Piontek T, Dhar A. A phase I, open-label, study of GSK2879552, a lysine-specific demethylase 1 (LSD1) inhibitor, in patients with relapsed/refractory small cell lung carcinoma (SCLC). Ann Oncol 2016. [DOI: 10.1093/annonc/mdw368.24] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open Abstract Collapse Key Words Collapse MESH Headings Collapse Grants Collapse
41	Robinson C, Samson P, Bradley J, Roach M, DeWees T, Waqar S, Baggstrom M, Govindan R, Higgins K, Simone C, Grover S, Puri V, Morgensztern D. Patterns of Care and Survival for Early Versus Delayed Radiation Therapy (RT) in Limited-Stage Small Cell Lung Cancer (LS-SCLC): A Review of the National Cancer Data Base. Int J Radiat Oncol Biol Phys 2016. [DOI: 10.1016/j.ijrobp.2016.06.1726] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022] Abstract Collapse Key Words Collapse MESH Headings Collapse Grants Collapse
42	Reck M, Horn L, Novello S, Barlesi F, Albert I, Juhasz E, Chung J, Fritsch A, Drews U, Rutstein M, Wagner A, Govindan R. Phase II study of roniciclib in combination with cisplatin/etoposide or carboplatin/etoposide as first-line therapy in subjects with extensive-disease small cell lung cancer (ED-SCLC). Ann Oncol 2016. [DOI: 10.1093/annonc/mdw389.04] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open Abstract Collapse Key Words Collapse MESH Headings Collapse Grants Collapse
43	Fracasso P, Freeman D, Simonsen K, Shen Y, Gupta M, Comprelli A, Gainor J, Hellmann M, Chow L, Forde P, Govindan R, Reilly T, Cassidy J. A phase 2, fast real-time assessment of combination therapies in immuno-oncology trial in patients with advanced non-small cell lung cancer (FRACTION-lung). Ann Oncol 2016. [DOI: 10.1093/annonc/mdw383.95] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open Abstract Collapse Key Words Collapse MESH Headings Collapse Grants Collapse
44	Iscoe N, Govindan R, Hossain A, Antonio BS, Chouaki N, Koczywas M, Vokes E, Senan S. The impact of staging by positron emission tomography (PET) on overall survival (OS) and progression-free survival (PFS) in the phase III PROCLAIM study. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw382.14] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open Abstract Collapse Key Words Collapse MESH Headings Collapse Grants Collapse
45	Weiner A, Speirs C, DeWees T, Rehman S, Molotievschi A, Velez M, Mullen D, Fergus S, Trovo M, Baggstrom M, Morgensztern D, Govindan R, Waqar S, Bradley J, Robinson C. Consolidation Chemotherapy Following Weekly Carboplatin-Paclitaxel Based Chemoradiation for Locally Advanced Non-Small Cell Lung Cancer Is Associated With Improved Overall and Disease-Free Survival. Int J Radiat Oncol Biol Phys 2016. [DOI: 10.1016/j.ijrobp.2016.06.1739] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022] Abstract Collapse Key Words Collapse MESH Headings Collapse Grants Collapse
46	Mornex F, Senan S, Hennequin C, Lartigau E, Brade A, Wang L, Vansteenkiste J, Dakhil S, Biesma B, Martinez Aguillo M, Aerts J, Govindan R, Rubio-Viqueira B, Lewanski C, Gandara D, Choy H, Mok T, Hossain A, Iscoe N, Treat J, Koustenis A, Chouaki N, Vokes E. PROCLAIM : résultats finaux de survie globale de l’essai de phase III : pemetrexed cisplatine ou étoposide cisplatine, plus radiothérapie thoracique suivie d’une chimiothérapie de consolidation dans le CBNPC non épidermoïde localement avancé. Rev Mal Respir 2016. [DOI: 10.1016/j.rmr.2015.10.674] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022] Abstract Collapse Key Words Collapse MESH Headings Collapse Grants Collapse
47	Barlesi F, Dingemans A, Ou I, Ahn J, Petris L, Kim D, Yang J, Hughes B, Lena H, Moro-Sibilot D, Bearz A, Viteri S, Mekhail T, Spira A, Zeaiter A, Bordogna W, Sturm C, Golding S, Morcos P, Govindan R. 3101 Updated efficacy and safety results from a global phase 2, open-label, single-arm study (NP28673) of alectinib in crizotinib-refractory ALK+ non-small-cell lung cancer (NSCLC). Eur J Cancer 2015. [DOI: 10.1016/s0959-8049(16)31742-7] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022] Abstract Collapse Key Words Collapse MESH Headings Collapse Grants Collapse
48	Cho B, Dy G, Govindan R, Kim D, Pennell N, Zalcman G, Besse B, Nogai H, Rajagopalan P, Ocker M, Barlesi F. 3100 Phase Ib/II study of the pan-cyclin-dependent kinase (CDK) inhibitor roniciclib (BAY 1000394) in combination with chemotherapy as first-line therapy in subjects with extensive disease small cell lung cancer (ED-SCLC). Eur J Cancer 2015. [DOI: 10.1016/s0959-8049(16)31741-5] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022] Abstract Collapse Key Words Collapse MESH Headings Collapse Grants Collapse
49	Pietanza M, Spigel D, Bauer T, Ready N, Glisson B, Morgensztern D, Robert F, Salgia R, Kochendorfer M, Patel M, Strickland D, Govindan R, Burris H, Rudin C, Dylla S. 7LBA Safety, activity, and response durability assessment of single agent rovalpituzumab tesirine, a delta-like protein 3 (DLL3)-targeted antibody drug conjugate (ADC), in small cell lung cancer (SCLC). Eur J Cancer 2015. [DOI: 10.1016/s0959-8049(16)31931-1] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022] Abstract Collapse Key Words Collapse MESH Headings Collapse Grants Collapse
50	Gerber DE, Oxnard GR, Govindan R. ALCHEMIST: Bringing genomic discovery and targeted therapies to early-stage lung cancer. Clin Pharmacol Ther 2015;97:447-50. [PMID: 25677079 DOI: 10.1002/cpt.91] [Citation(s) in RCA: 43] [Impact Index Per Article: 4.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/23/2015] [Accepted: 02/08/2015] [Indexed: 11/07/2022] Abstract The identification of druggable molecular alterations represents one of the greatest advances in cancer treatment. Such progress is particularly evident for lung cancer, which now has numerous molecularly defined subsets such as epidermal growth factor receptor (EGFR) mutations and anaplastic lymphoma kinase (ALK) rearrangements. However, understanding of the significance of these genomic alterations is largely limited to incurable, metastatic lung cancer. ALCHEMIST (Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial) is a National Cancer Institute-sponsored initiative to address these questions in earlier-stage disease. Collapse Key Words Collapse MESH Headings Collapse Grants Collapse